Codiak BioSciences, Inc. (CDAK)
Stock Price:
$9.50 USD
0.07 (0.74%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
176.61M |
| Revenue (ttm) |
622 |
| Net Income (ttm) |
-94.46M |
| Shares Out |
18.59M |
| EPS (ttm) |
-5.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$9.50 |
| Previous Close |
$9.43 |
| Change ($) |
0.07 |
| Change (%) |
0.74% |
| Day's Open |
9.55 |
| Day's Range |
9.13 - 9.66 |
| Day's Volume |
132,878 |
| 52-Week Range |
9.05 - 14.40 |
More Stats
| Market Cap |
176.61M |
| Enterprise Value |
172.99M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.59M |
| Float |
8.03M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-5.08 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
283,930.87 |
| PB Ratio |
n/a |
| Revenue |
622 |
| Operating Income |
n/a |
| Net Income |
-94.46M |
| Free Cash Flow |
n/a |
| Net Cash |
3.61M |
| Net Cash / Share |
0.19 |
| Gross Margin |
-9,503.70% |
| Operating Margin |
n/a |
| Profit Margin |
-15,186,977.49% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 0.39 | - |
| Gross Profit | 0.39 | - |
| Operating Income | -80.15 | -46.44 |
| Net Income | -77.96 | -44.54 |
| Shares Outstanding | 2.99 | 2.52 |
| Earnings Per Share | -30.66 | -23.07 |
| Operating Cash Flow | -1.70 | -30.57 |
| Capital Expenditures | -10.48 | -1.82 |
| Free Cash Flow | -12.18 | -32.39 |
| Cash & Equivalents | 83.75 | 88.86 |
| Total Debt | 9.57 | - |
| Net Cash / Debt | 74.18 | 88.86 |
| Assets | 116 | 97.66 |
| Liabilities | 94.01 | 5.63 |
| Book Value | -193 | -109 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Codiak BioSciences, Inc. |
| Country |
United States |
| Employees |
101 |
| CEO |
Douglas E. Williams |
Stock Information
| Ticker Symbol |
CDAK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CDAK |
| IPO Date |
October 14, 2020 |
Description
Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.